IN8bio to Present at Upcoming Investor Conferences

2024-02-26

细胞疗法临床1期临床2期免疫疗法

NEW YORK--(BUSINESS WIRE)-- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the following investor conferences in March: TD Cowen 44th Annual Health Care Conference Company presentation Monday, March 4, 2024, at 9:50 am ET 2nd Annual H.C. Wainwright Cell Therapy Virtual Conference Virtual company presentation Tuesday, March 26, 2024 A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at . About IN8bio IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogenic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells. IN8bio has initiated a Phase 2 trial of INB-400 in GBM in the United States and has two ongoing Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other hematological and solid tumor cancers. For more information visit .

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

New York State College of Agriculture & Life Sciences